Literature DB >> 7806975

Abnormalities of glycosphingolipid, sulfatide, and ceramide in the polycystic (cpk/cpk) mouse.

G D Deshmukh1, N S Radin, V H Gattone, J A Shayman.   

Abstract

Polycystic kidney disease is a disorder marked by aberrant renal tubular epithelial cell proliferation and transport abnormalities. Sphingolipids are ubiquitous membrane components implicated in several cellular functions including cell membrane sorting, signaling, growth, ion transport, and adhesion. To investigate a potential pathogenic role for sphingolipids in cystic kidney disease, we studied the sphingolipid content and associated enzymatic activities of the kidneys from cpk/cpk mice and their phenotypically normal litter mates. The neutral glycolipids, including glucosylceramide and lactosylceramide, displayed a striking increase in 3-week-old cpk/cpk mice as did the acidic lipid, ganglioside GM3. However, a correspondingly significant decrease in sulfoglycolipid and ceramide concentration was observed in the cpk/cpk kidneys. Glucosylceramide synthase activity was higher in the kidneys of the cpk/cpk mice than in those of the controls. Kinetic analysis of the glucosylceramide synthase revealed the presence of an endogenous activator in the cystic kidney. A marked decrease in sulfotransferase activity was observed in both whole kidney homogenates and in microsomal preparations that was consistent with the decrement in sulfolipid content. The increase in GM3, glucosyl- and lactosylceramide may therefore be the result of impaired sulfolipid synthesis at the 3-week time point. While sulfolipid and glucosylceramide concentrations are not different at 1 and 2 weeks of age, ceramide concentrations in cystic kidneys are significantly reduced compared to kidneys from phenotypically normal mice. These results suggest that sphingolipids may play a potential role in the proliferative and transport abnormalities associated with cystic renal disease and the development of azotemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7806975

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  18 in total

Review 1.  Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics.

Authors:  Alfred H Merrill
Journal:  Chem Rev       Date:  2011-09-26       Impact factor: 60.622

Review 2.  ADPKD current management and ongoing trials.

Authors:  Francesca Testa; Riccardo Magistroni
Journal:  J Nephrol       Date:  2019-12-18       Impact factor: 3.902

3.  Studies of the action of ceramide-like substances (D- and L-PDMP) on sphingolipid glycosyltransferases and purified lactosylceramide synthase.

Authors:  S Chatterjee; T Cleveland; W Y Shi; J Inokuchi; N S Radin
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

4.  Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models.

Authors:  Thomas A Natoli; Laurie A Smith; Kelly A Rogers; Bing Wang; Svetlana Komarnitsky; Yeva Budman; Alexei Belenky; Nikolay O Bukanov; William R Dackowski; Hervé Husson; Ryan J Russo; James A Shayman; Steven R Ledbetter; John P Leonard; Oxana Ibraghimov-Beskrovnaya
Journal:  Nat Med       Date:  2010-06-20       Impact factor: 53.440

5.  MALDI imaging MS reveals candidate lipid markers of polycystic kidney disease.

Authors:  Hermelindis Ruh; Theresia Salonikios; Jens Fuchser; Matthias Schwartz; Carsten Sticht; Christina Hochheim; Bernhard Wirnitzer; Norbert Gretz; Carsten Hopf
Journal:  J Lipid Res       Date:  2013-07-12       Impact factor: 5.922

6.  Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Jared J Grantham; Arlene B Chapman; Michal Mrug; Kyongtae T Bae; Bernard F King; Louis H Wetzel; Diego Martin; Mark E Lockhart; William M Bennett; Marva Moxey-Mims; Kaleab Z Abebe; Yan Lin; James E Bost
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-18       Impact factor: 8.237

Review 7.  Targeting Glycosphingolipid Metabolism to Treat Kidney Disease.

Authors:  James A Shayman
Journal:  Nephron       Date:  2016-03-09       Impact factor: 2.847

8.  Sulfatides are required for renal adaptation to chronic metabolic acidosis.

Authors:  Paula Stettner; Soline Bourgeois; Christian Marsching; Milena Traykova-Brauch; Stefan Porubsky; Viola Nordström; Carsten Hopf; Robert Koesters; Robert Kösters; Roger Sandhoff; Herbert Wiegandt; Carsten A Wagner; Hermann-Josef Gröne; Richard Jennemann
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

Review 9.  The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity?

Authors:  James A Shayman
Journal:  Trans Am Clin Climatol Assoc       Date:  2013

Review 10.  The consequences of genetic and pharmacologic reduction in sphingolipid synthesis.

Authors:  Raphael Schiffmann
Journal:  J Inherit Metab Dis       Date:  2014-08-28       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.